Clinical Trial: A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07899632) titled 'A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors' on Oct. 13.

Brief Summary: This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors. The main goals of this study are to:

* Find the recommended dose of MDSY-1240 that can be safely given to participants

* Learn more about the side effects and effectiveness of MDSY-1240

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Triple-Negative Breast Cancer (TNBC) Gastric Cancer (GC) Gastric Cancer Adenocarcinoma Metastatic Ovarian Canc...